Suggested remit: To appraise the clinical and cost effectiveness of lisocabtagene maraleucel within its marketing authorisation for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
 
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3887

Provisional Schedule

Draft guidance 14 November 2024 - 05 December 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Bristol-Myers Squibb (Lisocabtagene maraleucel)
Others Department of Health and Social Care
  NHS England
Patient carer groups Blood Cancer UK
  Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Accord Healthcare (carboplatin, cisplatin, cytarabine, gemcitabine) (confidentiality agreement not signed, not participating)
  Advanz Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Aspen (dexamethasone) (confidentiality agreement not signed, not participating)
  Baxter Healthcare (ifosfamide) (confidentiality agreement not signed, not participating)
  Cheplapharm Arzneimittel GmbH (etoposide) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Hameln Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, cisplatin, cytarabine, dexamethasone, gemcitabine) (confidentiality agreement not signed, not participating)
  Jazz Pharmaceuticals UK (cytarabine) (confidentiality agreement not signed, not participating)
  Martindale Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating)
  Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Pfizer (cytarabine, rituximab) (confidentiality agreement not signed, not participating)
  Roche Products (rituximab) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin, rituximab) (confidentiality agreement not signed, not participating)
  Sun Pharmaceutical (gemcitabine) (confidentiality agreement not signed, not participating)
  Synchrony Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Thame Laboratories (dexamethasone) (confidentiality agreement not signed, not participating)
  Wockhardt UK (dexamethasone) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics & Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
02 October 2024 Committee meeting
02 October 2024 Declaration of interests
04 March 2024 Invitation to participate
11 January 2024 - 08 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3887
11 January 2024 In progress. Scoping commencing
24 May 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
19 October 2021 Following information received from the company the timelines for this appraisal are currently to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.

For further information on our processes and methods, please see our CHTE processes and methods manual